Nutrien (NYSE:NTR) reported quarterly earnings of $2.49 per share which missed the analyst consensus estimate of $2.73 by 8.79 percent. This is a 758.62 percent increase over earnings of $0.29 per share from the same period last year.
Arcturus Therapeutics’s Return On Capital Employed Overview
Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter.
